HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects.
Clinical risk management
Incarcerated women
Medico legal aspects
Micro-elimination
Prison settings
Viral hepatitis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
07 Jul 2022
07 Jul 2022
Historique:
received:
22
11
2021
accepted:
23
06
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
Hepatitis C virus (HCV) infection is more frequent among incarcerated people than in general population. In the DAAs era, the short schedules and the low risk of adverse reactions, increased the number of HCV treatments. However, the most part of literature reports lack of incarcerated women inclusion in studies on field. Our aim is to assess the screening execution, HCV prevalence, and DAAs treatment among incarcerated women. A focused insight on quick vs standard diagnosis and staging approach will be also provided. Incarcerated women from 4 Italian regions' penitentiary institutes were included. HCV screening was executed with HCV saliva test (QuickOral Test We included 156 women, 89 (57%) were Italian, mean age was 41 ± 10 years, and 28 (17.9%) were people who inject drugs (PWIDs). Overall, the HCV seroprevalence was 20.5%. Being PWID and on opioid substitution therapy (OST) were significantly associated with serological status (p-value < 0.001). Of them, the 75.5% of patients had active infection, the most frequent genotype was 3a (50%). Among them, 4 (16.6%) and 6 (25%) had psychosis or alcohol abuse history. The 62.5%, 25% and 12.5% had low, intermediate, and advanced fibrosis, respectively. Out of the 24 HCV-RNA positive patients, the 75% underwent to DAAs treatment. The sustained virological response (SVR12) was achieved in 88.8% of cases. When evaluating the influence of quick diagnosis and staging methods vs standard phlebotomy and fibroscan HCV seroprevalence and active infections are very high among incarcerated women. More tailored interventions should be focused on HCV diagnosis and treatment in female prison population. The use of quick staging methods (FIB-4) is useful to increase SVR12 achievement without delays caused by the fibroscan
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV) infection is more frequent among incarcerated people than in general population. In the DAAs era, the short schedules and the low risk of adverse reactions, increased the number of HCV treatments. However, the most part of literature reports lack of incarcerated women inclusion in studies on field. Our aim is to assess the screening execution, HCV prevalence, and DAAs treatment among incarcerated women. A focused insight on quick vs standard diagnosis and staging approach will be also provided.
METHODS
METHODS
Incarcerated women from 4 Italian regions' penitentiary institutes were included. HCV screening was executed with HCV saliva test (QuickOral Test
RESULTS
RESULTS
We included 156 women, 89 (57%) were Italian, mean age was 41 ± 10 years, and 28 (17.9%) were people who inject drugs (PWIDs). Overall, the HCV seroprevalence was 20.5%. Being PWID and on opioid substitution therapy (OST) were significantly associated with serological status (p-value < 0.001). Of them, the 75.5% of patients had active infection, the most frequent genotype was 3a (50%). Among them, 4 (16.6%) and 6 (25%) had psychosis or alcohol abuse history. The 62.5%, 25% and 12.5% had low, intermediate, and advanced fibrosis, respectively. Out of the 24 HCV-RNA positive patients, the 75% underwent to DAAs treatment. The sustained virological response (SVR12) was achieved in 88.8% of cases. When evaluating the influence of quick diagnosis and staging methods vs standard phlebotomy and fibroscan
CONCLUSION
CONCLUSIONS
HCV seroprevalence and active infections are very high among incarcerated women. More tailored interventions should be focused on HCV diagnosis and treatment in female prison population. The use of quick staging methods (FIB-4) is useful to increase SVR12 achievement without delays caused by the fibroscan
Identifiants
pubmed: 35799126
doi: 10.1186/s12879-022-07565-2
pii: 10.1186/s12879-022-07565-2
pmc: PMC9264562
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
601Informations de copyright
© 2022. The Author(s).
Références
Lancet Gastroenterol Hepatol. 2021 May;6(5):391-400
pubmed: 33857445
Int J Drug Policy. 2018 Sep;59:50-53
pubmed: 29986272
Int J Drug Policy. 2021 Apr;90:103055
pubmed: 33310637
Am J Public Health. 2015 Jan;105(1):68-71
pubmed: 25393180
Hepatology. 2013 Oct;58(4):1215-24
pubmed: 23504650
Transfus Apher Sci. 2020 Aug;59(4):102811
pubmed: 32444279
N Engl J Med. 2014 May 15;370(20):1871-4
pubmed: 24827032
Healthcare (Basel). 2021 Sep 09;9(9):
pubmed: 34574960
PLoS One. 2019 Jun 3;14(6):e0217471
pubmed: 31158245
Am J Gastroenterol. 2018 Nov;113(11):1639-1648
pubmed: 29946175
Int J STD AIDS. 2017 Oct;28(12):1234-1238
pubmed: 28632479
PLoS One. 2020 Mar 10;15(3):e0229239
pubmed: 32155165
BMJ. 2017 May 22;357:j2277
pubmed: 28533264
Liver Int. 2021 Feb;41(2):271-275
pubmed: 33226730
Infection. 2017 Apr;45(2):131-138
pubmed: 28025726
Dig Liver Dis. 2020 May;52(5):541-546
pubmed: 32234417
Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162
pubmed: 26668814
J Forensic Leg Med. 2012 Nov;19(8):497-8
pubmed: 23084317
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309